Allergan’s Lumigan REMOVED by Carmark and 4 Insider Stock Analyses to Note

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

WellPoint Inc. (NYSE:WLP): Leerink believes that the acquisition of Amerigroup (NYSE:AGP), by Wellpoint, is beneficial because it diversifies the company’s revenue away from their commercial business. They noted, however, that the price paid is expensive. Leerink keeps a Market Perform rating on shares of Wellpoint.

Don’t Miss: The Coming Mini-Tablet WAR is Heating Up.

Cabot Oil & Gas Corporation (NYSE:COG): To reflect the company’s Pearsall joint venture, Ladenburg raised its price target for Cabot Oil & Gas. The firm reiterates a Buy rating on the stock.

Allegiant Travel Company (NASDAQ:ALGT): Citing the company’s better cost guidance, Imperial Capital raised its estimates and price target for Allegiant Travel. The firm maintains an Outperform rating on the stock.

Allergan Inc. (NYSE:AGN):  Carmark has removed Allergan’s ophthalmology product, Lumigan, from its 2013 formula coverage, this will impact 2013 earnings by 15c, RBC said.

Varian Medical Systems Inc. (NYSE:VAR): After CMS published proposed reductions in reimbursement rates for patients receiving  radiation therapy at clinics, Cantor Fitzgrerald noted that  the agency increased reimbursement rates for cancer patients receiving radiation therapy in hospitals. The firm thinks that CMS will moderate the rate cut in the final rule, and it believes that today’s decline in Varian is an overreaction.

Don’t Miss: Wall Street Brief: Alcoa Kicks Off EARNINGS Season, Google FINED $22.5M. 

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business